RemeGen Co. Ltd. Class H (HK:9995)
:9995
Top Page
RemeGen Co. Ltd. Class H
(9995)
Select Model
Select Model
Rating:65Neutral
Price Target:
HK$119.00
▲(3.30% Upside)
Action:ReiteratedDate:04/02/26
The score is driven primarily by improving fundamentals in 2025 (revenue acceleration, strong margins, return to profitability), but tempered by weak cash conversion and negative free cash flow. Technicals are supportive with strong trend and momentum, while a high P/E (~51.5) reduces valuation attractiveness.
Positive Factors
Revenue & Profitability Recovery
A sharp revenue rebound and return to positive net margins in 2025 indicate the business can scale commercial traction and convert sales into profit. This improvement supports sustainable operating leverage, funds R&D and commercialization, and reduces reliance on one-off accounting gains for future profitability.
Negative Factors
Weak Cash Generation & Negative FCF
Operating cash flow that lags reported earnings and persistently negative free cash flow reduce internal funding capacity. Over months, this elevates reliance on external financing, increasing dilution or refinancing risk and constraining the firm's ability to self-fund late-stage trials or commercial expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profitability Recovery
A sharp revenue rebound and return to positive net margins in 2025 indicate the business can scale commercial traction and convert sales into profit. This improvement supports sustainable operating leverage, funds R&D and commercialization, and reduces reliance on one-off accounting gains for future profitability.
Read all positive factors
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$84.11B
Dividend YieldN/A
Average Volume (3M)6.34M
Price to Earnings (P/E)51.5
Beta (1Y)1.48
Revenue Growth46.14%
EPS Growth39.56%
CountryHK
Employees2,999
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.47
Shares Outstanding208,581,240
10 Day Avg. Volume6,644,676
30 Day Avg. Volume6,343,592
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.84
Price to Sales (P/S)11.22
P/FCF Ratio-253.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$127.94Price Target Upside11.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)5.53
Revenue Forecast (FY)HK$6.73B
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
Company Description
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United ...
How the Company Makes Money
null...
RemeGen Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.17B | 1.72B | 1.08B | 767.77M | 1.42B |
| Gross Profit | 2.55B | 1.37B | 822.99M | 497.84M | 1.36B |
| EBITDA | 438.88M | -1.19B | -1.25B | -805.70M | 402.05M |
| Net Income | 690.19M | -1.47B | -1.51B | -997.84M | 276.26M |
Balance Sheet | |||||
| Total Assets | 7.25B | 5.50B | 5.53B | 6.02B | 4.16B |
| Cash, Cash Equivalents and Short-Term Investments | 2.42B | 759.53M | 709.07M | 2.19B | 1.76B |
| Total Debt | 2.20B | 2.67B | 1.26B | 165.03M | 102.78M |
| Total Liabilities | 3.55B | 3.51B | 2.09B | 1.04B | 712.79M |
| Stockholders Equity | 3.61B | 1.99B | 3.44B | 4.98B | 3.45B |
Cash Flow | |||||
| Free Cash Flow | -140.08M | -1.38B | -2.35B | -2.02B | -353.71M |
| Operating Cash Flow | 54.75M | -1.11B | -1.50B | -1.26B | 263.63M |
| Investing Cash Flow | -203.49M | -248.24M | -817.65M | -841.56M | -637.95M |
| Financing Cash Flow | 537.67M | 1.39B | 978.31M | 2.43B | -626.90M |
RemeGen Co. Ltd. Class H Technical Analysis
Positive
115.20
Price Trends
86.72
Positive
85.18
Positive
83.64
Positive
Market Momentum
5.61
Negative
71.97
Negative
82.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9995, the sentiment is Positive. The current price of 115.2 is above the 20-day moving average (MA) of 93.36, above the 50-day MA of 86.72, and above the 200-day MA of 83.64, indicating a bullish trend. The MACD of 5.61 indicates Negative momentum. The RSI at 71.97 is Negative, neither overbought nor oversold. The STOCH value of 82.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9995.
RemeGen Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
65 Neutral | HK$84.11B | 51.47 | 32.32% | ― | 46.14% | 39.56% | |
56 Neutral | HK$26.89B | -6.48 | -12.75% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.64B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$17.86B | -10.93 | -22.81% | ― | 23.87% | 30.08% |
* Healthcare Sector Average
HK:9995
RemeGen Co. Ltd. Class H
115.20
93.60
433.33%
HK:1548
Genscript Biotech
12.36
2.56
26.12%
HK:9688
Zai Lab Ltd
15.78
-5.82
-26.94%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
HK:2096
Simcere Pharmaceutical Group Limited
13.62
6.44
89.69%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
49.85
186.36%
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Wins NMPA Nod to Start Clinical Trial of Bispecific ADC RC288
Apr 1, 2026
RemeGen Co., Ltd. announced that China’s National Medical Products Administration has approved the Phase I/IIa clinical trial application for RC288, a bispecific antibody-drug conjugate for injection targeting PSMA and B7H3, to be tested as ...
RemeGen Boosts 2025 Revenue as Telitacicept Wins New Approvals and NRDL Access
Mar 27, 2026
RemeGen reported strong product sales revenue of about RMB2.31 billion for 2025, up 35.8% year on year, driven mainly by robust growth from its autoimmune therapy telitacicept and oncology drug disitamab vedotin. The performance underscores the co...
RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer
Mar 23, 2026
RemeGen has obtained approval from China’s National Medical Products Administration for a new indication of its flagship drug Disitamab Vedotin to treat adult patients with unresectable or metastatic HER2-low breast cancer with liver metasta...
RemeGen Schedules March 27 Board Meeting to Approve 2025 Annual Results
Mar 17, 2026
RemeGen Co., Ltd. has scheduled a board meeting for March 27, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The board will also consider whether to recommend a dividend, a ...
RemeGen Swings to Profit on Strong 2025 Revenue Growth
Feb 27, 2026
RemeGen Co., Ltd. reported a sharp improvement in its preliminary 2025 financial results, with total operating revenue rising 89.36% year on year to RMB3.25 billion and a swing from a significant loss to a net profit attributable to owners of the ...
RemeGen Forecasts 2025 Profit Turnaround on Surging Drug Sales and Global Licensing Deal
Jan 30, 2026
RemeGen Co., Ltd. has issued preliminary 2025 financial estimates indicating a sharp rebound in performance, with operating revenue expected to reach about RMB3.25 billion, up roughly 89% year on year, and net profit attributable to shareholders p...
RemeGen Completes RMB20 Million A-Share Buyback for Future Equity Incentives
Jan 21, 2026
RemeGen Co., Ltd. has completed a share repurchase plan for its A-shares on the Shanghai Stock Exchange, using RMB20 million of its own and/or self-raised funds to buy back 194,144 shares, or 0.0344% of its total share capital, via centralized bid...
RemeGen Raises Share Buyback Price Cap to Enable A‑Share Repurchase Plan
Jan 15, 2026
RemeGen Co., Ltd. has confirmed details of its previously approved A-share repurchase programme, under which it plans to use RMB20 million to RMB40 million of its own or self-raised funds to buy back shares via centralized bidding over a 12‑...
RemeGen Signs Up to US$5.6 Billion Global Licensing Deal with AbbVie for Cancer Drug RC148
Jan 12, 2026
RemeGen Co., Ltd. has signed an exclusive global licensing agreement with an AbbVie-controlled entity for RC148, its novel PD-1/VEGF-targeting bispecific antibody, granting AbbVie rights to develop, manufacture and commercialize the drug outside G...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.